Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

Ex-Southern California Real Estate Agent Selling $900K Condo Asks Why People Are Still Paying 5% Commission — 'Shelling Out 45K' For MLS Listing 'Seems Crazy'

View original at finance.yahoo.com
Ex-Southern California Real Estate Agent Selling $900K Condo Asks Why People Are Still Paying 5% Commission — 'Shelling Out 45K' For MLS Listing 'Seems Crazy' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Elf Labs' valuation growth exceeded 1,600% in under two years

    80% confidence
  • Former real estate agent questions why sellers still pay 5% commission ($45,000 on $900,000 condo) for loading information on MLS and maybe holding open house

    80% confidence
  • Rad AI's artificial intelligence technology helps transform data chaos into actionable insights for high-performing content with measurable ROI

    80% confidence
  • In New York, attorneys handle much of the real estate paperwork

    80% confidence
  • Paladin Power's ESS uses non-lithium, solid-state graphene battery technology as alternative to fire-prone storage solutions

    80% confidence
  • Arrived Homes' Private Credit Fund has historically paid an annualized dividend yield of 8.1%

    80% confidence
  • Commissions were always negotiable in theory, but recent changes made negotiation more explicit in practice

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com